uniQure Beheer

Beheer criteriumcontroles 1/4

De CEO uniQure is Matt Kapusta, benoemd in Dec2016, heeft een ambtstermijn van 7.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.58M, bestaande uit 9.6% salaris en 90.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.67% van de aandelen van het bedrijf, ter waarde $ 1.90M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 7.2 jaar.

Belangrijke informatie

Matt Kapusta

Algemeen directeur

US$6.6m

Totale compensatie

Percentage CEO-salaris	9.6%
Dienstverband CEO	7.9yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	7.2yrs

Recente managementupdates

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 09

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23

uniQure: Betting On Hemophilia-B Cure

Jan 18

Analyse CEO-vergoeding

Hoe is Matt Kapusta's beloning veranderd ten opzichte van uniQure's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$240m
Jun 30 2024	n/a	n/a	-US$285m
Mar 31 2024	n/a	n/a	-US$297m
Dec 31 2023	US$7m	US$635k	-US$308m
Sep 30 2023	n/a	n/a	-US$228m
Jun 30 2023	n/a	n/a	-US$187m
Mar 31 2023	n/a	n/a	-US$157m
Dec 31 2022	US$6m	US$609k	-US$127m
Sep 30 2022	n/a	n/a	-US$125m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	US$324m
Dec 31 2021	US$5m	US$583k	US$330m
Sep 30 2021	n/a	n/a	US$321m
Jun 30 2021	n/a	n/a	US$303m
Mar 31 2021	n/a	n/a	-US$139m
Dec 31 2020	US$4m	US$585k	-US$125m
Sep 30 2020	n/a	n/a	-US$166m
Jun 30 2020	n/a	n/a	-US$136m
Mar 31 2020	n/a	n/a	-US$124m
Dec 31 2019	US$4m	US$548k	-US$124m
Sep 30 2019	n/a	n/a	-US$105m
Jun 30 2019	n/a	n/a	-US$103m
Mar 31 2019	n/a	n/a	-US$92m
Dec 31 2018	US$3m	US$502k	-US$83m
Sep 30 2018	n/a	n/a	-US$90m
Jun 30 2018	n/a	n/a	-US$78m
Mar 31 2018	n/a	n/a	-US$78m
Dec 31 2017	US$4m	US$468k	-US$79m

Compensatie versus markt: De totale vergoeding ($USD 6.58M ) Matt } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.47M ).

Compensatie versus inkomsten: De vergoeding van Matt is gestegen terwijl het bedrijf verliesgevend is.

CEO

Matt Kapusta (52 yo)

7.9yrs

Tenure

US$6,584,919

Compensatie

Mr. Matthew Craig Kapusta, also known as Matt, serves as Director of Genezen Laboratories, Inc. since July 2024. He served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until Septe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew Kapusta	CEO & Executive Director	7.9yrs	US$6.58m	0.67% $ 1.9m
Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site	3.4yrs	US$2.12m	0.16% $ 443.4k
Richard Porter	Chief Business & Scientific Officer	1.1yrs	US$2.62m	0.068% $ 194.1k
Jeannette Potts	Chief Legal & Compliance Officer and Corporate Secretary	1.5yrs	US$2.54m	0.022% $ 63.8k
Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	no data	geen gegevens	geen gegevens
Amin Abujoub	Chief Technical Operations	less than a year	geen gegevens	geen gegevens
Tamara Tugal	Business Development Director	16.4yrs	geen gegevens	geen gegevens
Erin Boyer	Chief People & Culture Officer	less than a year	geen gegevens	geen gegevens
Walid Abi-Saab	Chief Medical Officer	1.4yrs	geen gegevens	0.24% $ 673.7k
Eileen Sawyer	Vice President of Global Medical Affairs	no data	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van QURE wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew Kapusta	CEO & Executive Director	9.8yrs	US$6.58m	0.67% $ 1.9m
Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	10.3yrs	geen gegevens	geen gegevens
Leonard Post	Independent Non-Executive Director	4.4yrs	US$412.46k	0.033% $ 93.5k
Michael Hayden	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Katherine High	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jack Kaye	Independent Non-Executive Director	8.4yrs	US$424.96k	0.013% $ 38.0k
Jesús Prieto	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Robin Ali	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Madhavan Balachandran	Independent Non-Executive Director	7.2yrs	US$412.46k	0.049% $ 138.9k
Jeremy Springhorn	Independent Non-Executive Director	7.2yrs	US$424.96k	0.049% $ 138.9k
David Meek	Independent Chairman of the Board	6.4yrs	US$444.96k	0.042% $ 118.4k
Robert Gut	Non-Executive Director	6.1yrs	US$404.96k	0.091% $ 258.2k

7.2yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van QURE wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.2 jaar).

uniQure Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Uniqure N.V. Announces Executive Changes

uniQure N.V., Annual General Meeting, Jun 18, 2024

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold US$177k worth of stock

CEO & Executive Director notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Recent updates

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS

Consensus revenue estimates decrease by 14%, EPS upgraded

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

New minor risk - Shareholder dilution

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Uniqure N.V. Announces Executive Changes

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 15%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold US$177k worth of stock

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates decrease by 33%, EPS upgraded

New minor risk - Share price stability

uniQure: The Valuation Got More Attractive

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Consensus revenue estimates fall by 35%

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 55%

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Operating Officer notifies of intention to sell stock

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. Announces Executive Changes

New minor risk - Share price stability

Consensus revenue estimates increase by 12%

Consensus revenue estimates fall by 36%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

CEO & Executive Director notifies of intention to sell stock

Consensus EPS estimates fall by 16%

CEO & Executive Director recently sold US$493k worth of stock

CEO & Executive Director notifies of intention to sell stock

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Independent Non-Executive Director exercised options and sold US$103k worth of stock

Independent Non-Executive Director exercised options and sold US$143k worth of stock

CEO & Executive Director recently sold US$149k worth of stock

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Independent Non-Executive Director notifies of intention to sell stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Consensus revenue estimates fall by 51%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind